Written and maintained by CASRAI Editorial Board
Last updated
Short answer
USP <1207> is the United States Pharmacopeia general chapter titled “Package Integrity Evaluation—Sterile Products”. It provides guidance on assuring the integrity of product packages, and its first subchapter, <1207.1>, explains how to select, develop and validate leak test methods across the product life cycle. It is guidance for manufacturers and quality staff, not a single test that can be run off the shelf.
What is USP <1207>? Definition and scope
According to the USP–NF preview of subchapter <1207.1> (“Package Integrity Testing in the Product Life Cycle—Test Method Selection and Validation”), chapter <1207> is titled “Package Integrity Evaluation—Sterile Products” and “provides guidance in the integrity assurance of product packages.” The subchapter states that it describes package integrity verification during three phases of the product life cycle and that it provides information on how to select, develop and validate leak test methods.
The subject matter is the package of a sterile product: whether the container and its closure keep the contents protected. In regulatory documents this is usually called container closure integrity testing (CCIT). The full text of the chapter is distributed through the USP–NF subscription.
How USP <1207> is used in practice: the three life-cycle phases
The preview of <1207.1> says package integrity verification is described for three phases. The checklist below pairs each phase with the question a quality reviewer would ask at that point.
| Life-cycle phase (USP–NF preview wording) | Question for a quality reviewer |
|---|---|
| Package development, and package processing and assembly validation | Was a leak test method selected and validated before the package design and assembly process were locked in? |
| Product manufacturing | Is integrity verified on product as it is manufactured, using a validated method? |
| Commercial product shelf-life stability assessments | Is integrity assessed at the stability time points for the product as marketed? |
The phase names are the preview’s; the questions in the right-hand column are a reading aid, not text from the chapter.
Deterministic and probabilistic methods: the FDA’s wording
The FDA’s August 2026 draft guidance on container closure systems for human drugs and biological products addresses the choice between these method families. It says the agency “encourages innovative, advanced, and deterministic integrity testing technologies,” that probabilistic methods “could be acceptable” but “can be challenging to design, develop, validate, and implement,” and that “all CCIT methods have advantages and disadvantages that should be considered prior to test selection.”
The draft’s Table 3 lists example methods by container type and states that the list is not exclusive. For vials and bottles (glass or plastic with a closure) it lists helium leak testing, pressure and/or vacuum decay, dye ingress and a mass extraction test. Other container types in the same table also list high voltage leak detection, internal pressurization (bubble emission), seal integrity testing and burst/creep testing. A footnote in the draft sends readers to USP <1207> and its subchapters for “a thorough discussion of the merits of various test methods for different types of CCSs.”
What the FDA says about container closure integrity
Aseptic processing guidance (September 2004)
The FDA’s CGMP guidance on sterile drug products produced by aseptic processing states that “a container closure system that permits penetration of microorganisms is unsuitable for a sterile product” and that damaged or defective units should be detected and removed during inspection of the final sealed product. It also says safeguards should be implemented to preclude shipment of product that may lack container closure integrity and lead to nonsterility. It names equipment suitability problems and incoming container or closure deficiencies as causes, and gives the example of vials fractured by faulty machinery or mishandling of bulk finished stock, which “has led to drug recalls.”
Container closure systems draft guidance (August 2026)
The draft is nonbinding. For sterile products it says CCIT and related data “should demonstrate that the proposed CCS maintains product sterility,” and that CCIT is used to evaluate integrity “to ensure the product is protected from ingress of environmental factors.” It says the agency encourages performing CCIT in lieu of sterility testing as a component of a stability program, and lists demonstrating that the container maintains its integrity at labeled storage conditions over expiry as a use of CCIT, and says that if an integrity failure is detected, manufacturers must investigate the root cause, citing 21 CFR 211.22(a) and 211.192.
For products stored at extreme low temperature, the draft notes that rubber stoppers can lose elastic properties and that a transient loss of seal integrity would not be captured when CCIT is conducted after the container is removed from the extreme conditions. It therefore says a test method that can be performed at extreme temperature (for example, freezing) should be considered.
Where it matters for labs, clinics and supply decisions
- Reading supplier and regulatory documents. Terms such as CCIT, dye ingress or helium leak testing in FDA documents trace back to this chapter family, so quality staff can recognise the underlying framework.
- Understanding where responsibility sits. The FDA documents above address manufacturers’ obligations (validated methods, inspection, root-cause investigation). They are not instructions to a clinic or laboratory receiving finished goods.
- Related CASRAI pages. For adjacent packaging and sterility topics see shelf life and packaging validation for medical devices, sterilization pouches, sterility assurance level and event-related sterility and sterile storage. For a freeze-dried product context, see the lyophilization guide.
Common misunderstandings
- “USP <1207> is one test.” It is a chapter of guidance, with a subchapter on selecting, developing and validating leak test methods. Method choice depends on the container and the phase.
- “The FDA requires a specific method.” The August 2026 draft is nonbinding, encourages deterministic technologies, and says probabilistic methods could be acceptable, with every method having trade-offs.
- “Room-temperature results cover every storage condition.” The draft says a transient seal loss at extreme low temperature would not be captured by a test run after the container is removed from those conditions.
- “A failed unit is just discarded.” The draft says an integrity failure triggers a root-cause investigation.
FAQ
What is USP <1207>?
It is the United States Pharmacopeia general chapter “Package Integrity Evaluation—Sterile Products”, which provides guidance in the integrity assurance of product packages. Its subchapter <1207.1> covers selecting, developing and validating leak test methods.
What does USP <1207> cover?
Per the <1207.1> preview, package integrity verification during three life-cycle phases: package development and processing/assembly validation, product manufacturing, and commercial shelf-life stability assessments.
Does the FDA require a particular container closure integrity test?
The August 2026 draft guidance is nonbinding. It encourages deterministic technologies, says probabilistic methods could be acceptable, and notes that every method has advantages and disadvantages to weigh before selection.
What happens when an integrity failure is found?
The draft guidance says manufacturers must investigate the root cause and implement appropriate corrective actions, citing 21 CFR 211.22(a) and 211.192.
Sources
All links checked 2026-10-29.
- USP–NF, <1207.1> Package Integrity Testing in the Product Life Cycle—Test Method Selection and Validation (preview): https://doi.usp.org/USPNF/USPNF_M9407_02_01.html
- U.S. FDA, draft guidance Container Closure Systems for Human Drugs and Biological Products (August 2026): https://www.fda.gov/media/194220/download
- U.S. FDA, Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice (September 2004): https://www.fda.gov/media/71026/download
